Yong June Choi, Jaewoo Park, Hyoyi Choi, Su-Jin Oh, Jin-Hee Park, Miso Park, Ji Won Kim, Yoon-Gyoon Kim, Yong-Chul Kim, Myung Jin Kim, Keon Wook Kang
Acute myeloid leukemia (AML) is a prevalent form of leukemia in adults. As its survival rate is low, there is an urgent need for new therapeutic options. In AML, FMS-like tyrosine kinase 3 (FLT3) mutations are common and have negative outcomes. However, current FLT3-targeting agents, Midostaurin and Gilteritinib, face two significant issues, specifically the emergence of acquired resistance and drug-related adverse events leading to treatment failure. Rearranged during transfection (RET), meanwhile, is a proto-oncogene linked to various types of cancer, but its role in AML has been limited...
June 29, 2023: Biomedicine & Pharmacotherapy